SARS-CoV-2 (COVID-19) registry for oncological and hematological patients in Germany

SARS-CoV-2 (COVID-19) registry for oncological and hematological patients in Germany - CoRe (ADHOK)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023012

Enrollment

170

Registered

2020-10-27

Start date

2020-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, SARS-CoV-2 infection Malignant tumors Hematological diseases (MDS, MPS, AA, ITP, PNH)

Interventions

Group 1: Retrospective investigation of the clinical course of SARS-CoV-2 infection in oncological and hematological patients in Germany. The data is collected anonymously and is recorded in an eCRF (

2. Details of tumor disease

3. Details of tumor treatment

4. Laboratory parameters

5. Course and outcome of the SARS-CoV-2 infection.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Confirmed SARS-CoV-2 infection using PCR and 2a. the presence of a malignant underlying disease (active or up to a maximum of 5 years ago) or 2b. the presence any of the following hematological disease: Myelodysplastic Syndrome (MDS), Myeloproliferative Syndrome (MPS), Aplastic Anemia (AA), Immune Thrombocytopenia (ITP), Paroxysmal Nocturnal Hemoglobinuria (PNH)

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Course of SARS-CoV2 infection	—

Countries

Germany

Contacts

Public ContactRomina Rösch

Klinikum rechts der Isar der Technischen Universität München

romina.roesch@tum.de; core.adhok@gmail.com+49 174 1823924

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 15, 2026